在接受过大量烷化剂化疗预处理的神经内分泌肿瘤（NET）患者中，177Lu-奥曲肽肽受体放射性核素治疗（PRRT）后发生骨髓增生异常综合征和急性髓系白血病的风险较高。 - Suppr

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.

作者信息

Brieau Bertrand, Hentic Olivia, Lebtahi Rachida, Palazzo Maxime, Ben Reguiga Makrem, Rebours Vinciane, Maire Frederique, Hammel Pascal, Ruszniewski Philippe, Fenaux Pierre

机构信息

Service de gastro-entérologie et pancréatologieHôpital Beaujon, AP-HP, Université Paris Diderot, Clichy, France.

Service de médecine nucléaireHôpital Beaujon, AP-HP, Université Paris Diderot, Clichy, France.

出版信息

Endocr Relat Cancer. 2016 May;23(5):L17-23. doi: 10.1530/ERC-15-0543. Epub 2016 Mar 1.

DOI:10.1530/ERC-15-0543

PMID:26932783

Abstract

摘要

相似文献

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.

Endocr Relat Cancer. 2016 May;23(5):L17-23. doi: 10.1530/ERC-15-0543. Epub 2016 Mar 1.

Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.

Neuroendocrinology. 2014;99(2):108-17. doi: 10.1159/000362558. Epub 2014 Apr 4.

Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.

Endocr Relat Cancer. 2013 Oct 14;20(6):825-31. doi: 10.1530/ERC-13-0254. Print 2013 Dec.

Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?

Neuroendocrinology. 2016;103(5):560-6. doi: 10.1159/000441604. Epub 2015 Nov 5.

Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.

Cancer Biother Radiopharm. 2016 Aug;31(6):189-98. doi: 10.1089/cbr.2016.2035. Epub 2016 Jul 15.

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.

J Nucl Med. 2013 Nov;54(11):1857-61. doi: 10.2967/jnumed.112.119347. Epub 2013 Sep 5.

Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.

Oncotarget. 2017 Apr 11;8(15):25669-25678. doi: 10.18632/oncotarget.12900.

Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.

Endocrine. 2019 Nov;66(2):417-424. doi: 10.1007/s12020-019-01894-0. Epub 2019 Mar 14.

Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.

Leuk Lymphoma. 2015;56(8):2468-9. doi: 10.3109/10428194.2014.999327. Epub 2015 Jan 21.

Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.

Nuklearmedizin. 2017 Jun 12;56(3):N19-N21. doi: 10.3413/Nukmed-0863-16-11. Epub 2017 Mar 30.

引用本文的文献

Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells.

Theranostics. 2025 May 25;15(13):6497-6515. doi: 10.7150/thno.113354. eCollection 2025.

Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study.

JCO Precis Oncol. 2024 Jun;8:e2400143. doi: 10.1200/PO.24.00143.

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade.

Front Endocrinol (Lausanne). 2023 Nov 20;14:1187870. doi: 10.3389/fendo.2023.1187870. eCollection 2023.

Recombinant α-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a Lu-DOTATATE Mouse Radiation Model.

Biomolecules. 2023 Jun 1;13(6):928. doi: 10.3390/biom13060928.

Screening for Clonal Hematopoiesis for Mitigating the Risk of Hematopoietic Neoplasms after PRRT.

World J Nucl Med. 2023 Apr 28;22(2):150-151. doi: 10.1055/s-0043-1764308. eCollection 2023 Jun.

A practical proposal on treatment sequencing of metastatic well-differentiated neuroendocrine tumours.

Ther Adv Med Oncol. 2023 Apr 29;15:17588359231171041. doi: 10.1177/17588359231171041. eCollection 2023.

Peptide Receptor Radionuclide Therapy.

J Clin Endocrinol Metab. 2022 Nov 25;107(12):3199-3208. doi: 10.1210/clinem/dgac574.

Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome.

Cureus. 2022 Feb 19;14(2):e22392. doi: 10.7759/cureus.22392. eCollection 2022 Feb.

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies.

Cancers (Basel). 2021 Dec 28;14(1):129. doi: 10.3390/cancers14010129.

Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns.

J Nucl Med. 2021 Dec;62(Suppl 3):23S-35S. doi: 10.2967/jnumed.121.262751.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献